Nasdaq4d
22nd Century Group Supports FDA's Proposed Reduced Nicotine Content Standard Following OMB Review Completion
The FDA spokesperson indicated that the policy could ... 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should ...
Nasdaq3d
Firefly Neuroscience Advances Brain Age Assessment Research with FDA-Cleared BNA™ Technology
Firefly (NASDAQ: AIFF) is an Artificial Intelligence ... for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology ...
Nasdaq4d
SeaStar Medical Receives FDA Approval for SCD-ADULT Study Funded by $3.6 Million NIH Grant
FDA approves SeaStar Medical's SCD-ADULT study ... check out Quiver Quantitative's insider trading dashboard. (Nasdaq: ICU), a commercial-stage medical device company developing proprietary ...
Nasdaq3d
22nd Century Group's VLN Reduced Nicotine Cigarettes Gain FDA Authorization Amid New Smoking Reduction Policies
22nd Century Group, Inc. has been highlighted in a Washington Post article discussing new FDA policies aimed at reducing the health risks associated with smoking, particularly through the ...
Nasdaq4d
FDA Accepts Eisai And Biogen's BLA For Subcutaneous LEQEMBI For Early Alzheimer's Disease
The US FDA accepted Eisai's Supplemental Biologics ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
Nasdaq4d
NeurAxis, Inc. CEO Brian Carrico Shares 2024 Achievements and Vision for 2025 in Shareholder Letter
Notable milestones in 2024 included the expansion of IB-Stim’s patient range, increased insurance coverage, and the receipt of FDA clearances for both IB-Stim and RED, alongside the approval of ...
Nasdaq4d
Eisai and Biogen Announce FDA Acceptance of Lecanemab Subcutaneous Autoinjector Application for Alzheimer's Disease Treatment
Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. FDA has accepted Eisai's Biologics ... “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...
Nasdaq3d
Ocular Therapeutix Enrolls 311 Subjects in SOL-R Trial of AXPAXLI for Wet AMD, Prepares to Address Diabetic Retinopathy in 2025
The need for FDA feedback in H1 2025 on the clinical trial ... Jan. 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical ...
Nasdaq5d
Roche's New Test For B-Cell Lymphoma Obtains FDA Clearance
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Nasdaq4d
BridgeBio Pharma Reports Strong Early Demand for Attruby and Updates on Phase 3 Clinical Trials
BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion ... Jan. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the ...
Nasdaq3d
Immuron Limited Submits Phase 2 Clinical Study Report for Travelan® (IMM-124E) to FDA, Achieving Significant Immunology and Microbiome Results
Immuron Limited announced the submission of the Clinical Study Report for its Phase 2 clinical trial of Travelan® (IMM-124E) to the FDA, which demonstrated ... (ASX: IMC, NASDAQ: IMRN), is ...
Nasdaq4d
Top 5 Small-cap Pharma Stocks (Updated January 2025)
Corvus is another NASDAQ pharma stock that saw significant gains in the last half of 2024. The growth in its share price got its first major boost in early August when the FDA granted fast track ...